RUC. Repositorio da Universidade da Coruña
Publicación
Artículo científico (JournalArticle)
Encapsulation of Transforming Growth Factor-β3 in Poly(hydroxybutyrate-co-hydroxyvalerate) Nanoparticles for Enhanced Cartilage Tissue Engineering
[Abstract] Poly(hydroxybutyrate-co-hydroxyvalerate) (PHBV) is a naturally occurring biopolymer belonging to the polyhydroxyalkanoate (PHA) family. Due to its excellent properties (biocompatible, biodegradable, and non-toxic), this biopolymer is presented as a very suitable option for use in regenerative therapy as a drug delivery system (DDS). The protein encapsulated in this study is transforming growth factor β3 (TGF-β3), which plays a key role in the chondrogenic differentiation of mesenchymal stem cells (MSCs). The main objective of this work is to evaluate the efficacy of PHBV nanoparticles (NPs) produced from a dairy by-product (whey) as a DDS of TGF-β3 for cartilage regeneration and extracellular matrix (ECM) synthesis and to reduce the complications associated with multiple high doses of TGF-β3 in its free form. For this purpose, biopolymer cytotoxicity, factor release, cell viability, cell proliferation, and differentiation were analyzed. The results showed that the biomaterial purified with chloroform and ethanol, either by single or double precipitation, was not toxic to cells. A sustained release profile was observed, reaching its maximum around day 4. The TGF-β3 NPs promoted the differentiation of MSCs into chondrocytes and the formation of ECM. In conclusion, PHBV demonstrated its potential as an optimal material for DDSs in cartilage regenerative therapy, effectively addressing the key challenge of the need for a single delivery method to reduce complications associated with multiple high doses of TGF-β3., Instituto de Salud Carlos III—General Subdirection of Assessment and Promotion of Research—European Regional Development Fund (FEDER) “A way of making Europe” (PI20/00933) and the Spanish Ministry of Economy and Competitiveness (MINECO) through European FEDER funds (PID2023-151067OB-I00), ayudas para proyectos Semilla-Disruptivos entre grupos del CICA 2021 (POLIBIOMED) of Universidade da Coruña, Grupos con Potencial de Crecemento (ED431B 2020/55 and ED431B 2023/58), Grupos de Referencia Competitiva (ED431C 2021/55) of Xunta de Galicia, and proyectos de Desarrollo y Transferencia 2022 and 2024 of Fundación Pública Gallega de Investigación Biomédica (INIBIC). A.I.R.-C. is currently employed by the Grupos con Potencial de Crecemento, Xunta de Galicia project (ED431B 2023/58).